NCT04617054 2026-01-21
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Nuvation Bio Inc.
Phase 2 Terminated
Nuvation Bio Inc.
Jiangsu HengRui Medicine Co., Ltd.
Gilead Sciences
Klus Pharma Inc.
Gilead Sciences
Shanghai Jiatan Pharmatech Co., Ltd
InventisBio Co., Ltd
Debiopharm International SA
Beijing Biostar Pharmaceuticals Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Partner Therapeutics, Inc.
Refnot-Pharm Ltd
Shanghai Henlius Biotech
Idera Pharmaceuticals, Inc.
Athenex, Inc.
NantPharma, LLC
Pfizer